[Cancer Management and Research] Although thin melanomas have an excellent prognosis after sufficient surgical treatment, melanoma disease in advanced stages still proves to be a therapeutic challenge. In the last several years, new therapeutic strategies have emerged.
[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). The etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) are discussed.
Research from the ESMO 2014 Congress suggest that combination therapies may improve the rate of survival for patients with melanoma.
Over the past decade, there has been significant progress in the development of novel cancer therapies.
[Breast Cancer (Auckl)] Human epidermal growth factor receptor-2 is overexpressed in up to 30% of breast cancers; indicative of poor prognosis.
[Cancer Control] Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success.
Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.
[Biomark Cancer] Biomarkers can provide great opportunities in the management of the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer.
Certain oral contraceptives may increase breast cancer risk, but researchers caution that the risk is small, if it exists at all.
[Clin Med Insights Ear Nose Throat] 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is used to monitor treatment response after definitive (chemo)radiotherapy for head and neck squamous cell carcinoma, but its usefulness remains controversial.
[Lymphoma and Chronic Lymphocytic Leukemias] Biomarker-driven chemotherapeutics is becoming a critical part of the state-of-the-art treatment in early- and late-phase clinical trials involving patients with T-cell lymphoma.
Diarrhea is a treatment symptom as common as hair loss but with deadlier implications.
Rate of cervical cancer in African-American women is higher than what was previously recognized.
The protocol was developed to guide clinicians who have limited medical intervention options.
Oncologists need more information on the factors that lead to nonadherence in order to actively prevent it.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|